LANTHEUS HOLDINGS INC. - COMMON STOCK

Lantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer

27 1 2022 07:30:00 提供 Nasdaq GlobeNewswire

Lantheus Appoints Vivian Yao as Chief Human Resources Officer

01 12 2021 07:30:00 提供 Nasdaq GlobeNewswire

Lantheus Announces PYLARIFY AI™ is Now Available

29 11 2021 07:30:00 提供 Nasdaq GlobeNewswire

Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022

22 11 2021 07:30:00 提供 Nasdaq GlobeNewswire

Lantheus Holdings Announces Presentations Featuring PYLARIFY® (Piflufolastat F 18), its PSMA-Targeted Prostate Cancer Imaging Agent, at Key Scientific Meetings

17 11 2021 07:30:00 提供 Nasdaq GlobeNewswire

Lantheus Holdings to Present at the 4th Annual Evercore ISI HealthCONx Conference

16 11 2021 15:30:00 提供 Nasdaq GlobeNewswire

Lantheus Holdings, Inc. Reports Third Quarter 2021 Financial Results

04 11 2021 06:00:03 提供 Nasdaq GlobeNewswire

Lantheus Holdings to Present at Upcoming Investor Conferences

28 10 2021 15:30:00 提供 Nasdaq GlobeNewswire

Lantheus Holdings to Host Third Quarter 2021 Earnings Conference Call and Webcast on November 4, 2021 at 8:00 a.m. Eastern Time

21 10 2021 07:00:01 提供 Nasdaq GlobeNewswire

Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network® (NCCN) Guidelines for Prostate Cancer

13 9 2021 07:00:03 提供 Nasdaq GlobeNewswire